FDA Estrogen Guidance Recommends Labeling Changes On Dementia Risk
FDA is recommending hormone replacement therapy class labeling changes to include new dementia risk information on estrogen-alone therapy in a 1draft guidance on noncontraceptive estrogen drug products
You may also be interested in...
FDA will make significant changes to a 2003 FDL-1draft guidance on estrogen products and reissue a new draft
FDA is recommending a hormone replacement therapy class "black box" warning on an increased risk of dementia with use of estrogen and combination estrogen/progestin products
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011